IGC Pharma Statistics
Total Valuation
IGC Pharma has a market cap or net worth of $23.51 million. The enterprise value is $23.31 million.
Important Dates
The last earnings date was Tuesday, February 18, 2025, before market open.
| Earnings Date | Feb 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
IGC Pharma has 79.69 million shares outstanding. The number of shares has increased by 29.68% in one year.
| Current Share Class | 79.69M |
| Shares Outstanding | 79.69M |
| Shares Change (YoY) | +29.68% |
| Shares Change (QoQ) | +2.14% |
| Owned by Insiders (%) | 9.29% |
| Owned by Institutions (%) | 20.91% |
| Float | 72.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.45 |
| Forward PS | 17.79 |
| PB Ratio | 3.92 |
| P/TBV Ratio | 5.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 18.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.04.
| Current Ratio | 1.15 |
| Quick Ratio | 0.21 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -115.06% and return on invested capital (ROIC) is -69.70%.
| Return on Equity (ROE) | -115.06% |
| Return on Assets (ROA) | -54.70% |
| Return on Invested Capital (ROIC) | -69.70% |
| Return on Capital Employed (ROCE) | -138.61% |
| Revenue Per Employee | $18,448 |
| Profits Per Employee | -$131,478 |
| Employee Count | 67 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 0.36 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.80% in the last 52 weeks. The beta is 1.45, so IGC Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | -32.80% |
| 50-Day Moving Average | 0.30 |
| 200-Day Moving Average | 0.36 |
| Relative Strength Index (RSI) | 52.94 |
| Average Volume (20 Days) | 261,894 |
Short Selling Information
The latest short interest is 792,786, so 0.99% of the outstanding shares have been sold short.
| Short Interest | 792,786 |
| Short Previous Month | 943,850 |
| Short % of Shares Out | 0.99% |
| Short % of Float | 1.10% |
| Short Ratio (days to cover) | 2.02 |
Income Statement
In the last 12 months, IGC Pharma had revenue of $1.24 million and -$8.81 million in losses. Loss per share was -$0.12.
| Revenue | 1.24M |
| Gross Profit | 636,000 |
| Operating Income | -8.90M |
| Pretax Income | -13.30M |
| Net Income | -8.81M |
| EBITDA | -8.27M |
| EBIT | -8.90M |
| Loss Per Share | -$0.12 |
Full Income StatementBalance Sheet
The company has $470,000 in cash and $270,000 in debt, giving a net cash position of $200,000 or $0.00 per share.
| Cash & Cash Equivalents | 470,000 |
| Total Debt | 270,000 |
| Net Cash | 200,000 |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 6.26M |
| Book Value Per Share | 0.08 |
| Working Capital | 394,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.59 million and capital expenditures -$109,000, giving a free cash flow of -$4.70 million.
| Operating Cash Flow | -4.59M |
| Capital Expenditures | -109,000 |
| Free Cash Flow | -4.70M |
| FCF Per Share | -$0.06 |
Full Cash Flow StatementMargins
| Gross Margin | 51.46% |
| Operating Margin | -720.06% |
| Pretax Margin | -712.70% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IGC Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.68% |
| Shareholder Yield | -29.68% |
| Earnings Yield | -37.47% |
| FCF Yield | -19.99% |
Analyst Forecast
The average price target for IGC Pharma is $3.88, which is 1,215.25% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.88 |
| Price Target Difference | 1,215.25% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on April 19, 2013. It was a reverse split with a ratio of 0.1:1.
| Last Split Date | Apr 19, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.1:1 |
Scores
IGC Pharma has an Altman Z-Score of -15.44 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.44 |
| Piotroski F-Score | 4 |